132,143 Shares in Repligen Co. (NASDAQ:RGEN) Bought by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 132,143 shares of the biotechnology company’s stock, valued at approximately $19,021,000. Segall Bryant & Hamill LLC owned about 0.24% of Repligen at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of RGEN. Vanguard Group Inc. lifted its position in shares of Repligen by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock valued at $734,251,000 after acquiring an additional 56,723 shares during the period. Conestoga Capital Advisors LLC increased its stake in Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after purchasing an additional 6,872 shares in the last quarter. DF Dent & Co. Inc. raised its holdings in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the period. New York State Common Retirement Fund boosted its position in shares of Repligen by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock worth $83,693,000 after purchasing an additional 14,398 shares in the last quarter. Finally, Stephens Investment Management Group LLC grew its stake in shares of Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after buying an additional 37,057 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $141.95 on Wednesday. The company has a market capitalization of $7.97 billion, a PE ratio of -278.33, a PEG ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock’s 50 day moving average price is $155.62 and its 200-day moving average price is $148.36. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $187.25.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. On average, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on RGEN shares. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Repligen presently has an average rating of “Hold” and an average price target of $178.64.

Insider Activity at Repligen

In related news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.